(4-(CARBOXY METHOXY)-3-CHLOROPHENYL) (5,5-DIETHYL-2,4,6(1H,3H,5H)-PYRIMIDINE-TRIO NATO)-O2-MERCURY, MONOSODIUM SALT Toxicity Data With Reference
1. | | ivn-rbt LDLo:20 mg/kg | | JPETAB Journal of Pharmacology and Experimental Therapeutics. 41 (1931),21. |
(4-(CARBOXY METHOXY)-3-CHLOROPHENYL) (5,5-DIETHYL-2,4,6(1H,3H,5H)-PYRIMIDINE-TRIO NATO)-O2-MERCURY, MONOSODIUM SALT Consensus Reports
Mercury and its compounds are on the Community Right-To-Know List.
(4-(CARBOXY METHOXY)-3-CHLOROPHENYL) (5,5-DIETHYL-2,4,6(1H,3H,5H)-PYRIMIDINE-TRIO NATO)-O2-MERCURY, MONOSODIUM SALT Safety Profile
(4-(CARBOXY METHOXY)-3-CHLOROPHENYL) (5,5-DIETHYL-2,4,6(1H,3H,5H)-PYRIMIDINE-TRIO NATO)-O2-MERCURY, MONOSODIUM SALT Standards and Recommendations
OSHA PEL: CL 0.1 mg(Hg)/m3 (skin)
ACGIH TLV: TWA 0.1 mg(Hg)/m3 (skin); BEI: 35 µg/g creatinine total inorganic mercury in urine preshift; 15 µg/g creatinine total inorganic mercury in blood at end of shift at end of workweek.
DFG MAK: Confirmed Animal Carcinogen with Unknown Relevance to Humans
NIOSH REL: (Mercury, Aryl and Inorganic) CL 0.1 mg/m3 (skin)